Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$2.87
-$0.02(-6.92%)
At close: 4:00 PM EDT
$2.87
-$0.02(-6.92%)
Day’s Range― - ―
52-Week Range$2.14 - $16.80
Previous CloseN/A
Volume35.26K
Average Volume (3M)101.31K
Market Cap
$1.43M
Enterprise Value$7.79
Total Cash (Recent Filing)$2.85M
Total Debt (Recent Filing)$3.58M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-62160.00
Shares Outstanding516,938
10 Day Avg. Volume127,573
30 Day Avg. Volume101,310
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Expanded CDMO CapabilitiesThe acquisition creates a broader CDMO platform spanning biologics, sterile injectables and small-molecule APIs. This can diversify revenue, improve customer coverage and support utilization growth as commercial activity scales across two sites.
Early Commercial TractionRevenue growth and signed customer commitments indicate that the expanded CDMO platform is beginning to attract demand. Sustained conversion and repeat business could establish a more recurring commercial base beyond the company’s earlier R&D focus.
Improved Balance SheetPositive equity and debt below equity provide a stronger financial foundation than in 2022–2023, when capitalization was strained. This improves flexibility while management works to expand operations, although continued losses could erode that benefit.
Bears Say
Persistent Cash Burn And Funding DependenceThe business does not currently fund operations internally, leaving it dependent on commercial growth, grants or external capital. A limited cash balance increases execution pressure and could constrain investment in manufacturing and proprietary programs.
Large Operating LossesThe two-site cost structure currently exceeds the revenue base, producing negative gross and operating margins. Profitability depends on materially higher utilization and pricing, leaving earnings quality weak until the CDMO platform reaches scale.
Execution And Revenue-recognition RiskSigned orders provide visibility but do not guarantee near-term revenue or cash collection. Delays in delivery, customer programs or invoicing could postpone the utilization ramp and prolong losses, liquidity pressure and reliance on financing.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $2.14 and its highest was $16.80 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $1.43M.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Dec 02, 2026 which is in 94 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Aug 20, 2026. The company reported -$3.662 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 516,938 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$3.662 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.338%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
0.37% Other Institutional Investors
99.63% Public Companies and
Individual Investors